These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 20121626)

  • 1. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy.
    An X; Ding PR; Xiang XJ; Wang ZQ; Wang FH; Feng F; Jiang WQ; He YJ; Xu RH; Li YH
    Biomarkers; 2010 May; 15(3):243-8. PubMed ID: 20121626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
    Li YH; An X; Xiang XJ; Wang ZQ; Wang FH; Feng F; Jiang WQ; He YJ; Xu RH
    Ai Zheng; 2009 Sep; 28(9):939-44. PubMed ID: 19728911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer.
    Sørbye H; Dahl O
    Acta Oncol; 2004; 43(5):495-8. PubMed ID: 15360055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy.
    Strimpakos AS; Cunningham D; Mikropoulos C; Petkar I; Barbachano Y; Chau I
    Ann Oncol; 2010 May; 21(5):1013-9. PubMed ID: 19861580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinoembryonic antigen in monitoring of response to cetuximab plus FOLFIRI or FOLFOX-4 in patients with metastatic colorectal cancer.
    Tsai HL; Chang YT; Chu KS; Chen CF; Yeh YS; Ma CJ; Wu DC; Kuo CH; Chan HM; Sheen MC; Wang JY
    Int J Biol Markers; 2008; 23(4):244-8. PubMed ID: 19199273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer.
    Ailawadhi S; Sunga A; Rajput A; Yang GY; Smith J; Fakih M
    Oncology; 2006; 70(1):49-53. PubMed ID: 16446549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
    Weihrauch MR; Ansén S; Jurkiewicz E; Geisen C; Xia Z; Anderson KS; Gracien E; Schmidt M; Wittig B; Diehl V; Wolf J; Bohlen H; Nadler LM
    Clin Cancer Res; 2005 Aug; 11(16):5993-6001. PubMed ID: 16115944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer.
    Gholam D; Giacchetti S; Brézault-Bonnet C; Bouchahda M; Hauteville D; Adam R; Ducot B; Ghémard O; Kustlinger F; Jasmin C; Lévi F
    Oncologist; 2006; 11(10):1072-80. PubMed ID: 17110626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.
    Kaufman HL; Lenz HJ; Marshall J; Singh D; Garett C; Cripps C; Moore M; von Mehren M; Dalfen R; Heim WJ; Conry RM; Urba WJ; Benson AB; Yu M; Caterini J; Kim-Schulze S; Debenedette M; Salha D; Vogel T; Elias I; Berinstein NL
    Clin Cancer Res; 2008 Aug; 14(15):4843-9. PubMed ID: 18676757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carcinoembryonic antigen half-life is an early predictor of therapeutic effects in induction chemotherapy for liver metastases from colorectal cancer.
    Nagai Y; Beppu T; Sakamoto Y; Miyamoto Y; Hayashi H; Nitta H; Imai K; Masuda T; Okabe H; Hirashima K; Imamura Y; Baba Y; Chikamoto A; Baba H
    Anticancer Res; 2014 Oct; 34(10):5529-35. PubMed ID: 25275051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
    Ng SL; Burns WI; Snyder RD; Newnham GM; McLachlan SA; Liew D; Dowling AJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):172-9. PubMed ID: 22524576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors associated with primary cancer in curatively resected stage IV colorectal cancer.
    Huh JW; Lee WY; Park YA; Cho YB; Yun SH; Kim HC; Chun HK
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):435-41. PubMed ID: 24414039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
    Martinez J; Martin C; Chacon M; Korbenfeld E; Bella S; Senna S; Richardet E; Coppola F; Bas C; Hidalgo J; Escobar E; Reale M; Smilovich AM; Wasserman E
    Am J Clin Oncol; 2006 Feb; 29(1):45-51. PubMed ID: 16462502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
    Scartozzi M; Sobrero A; Gasparini G; Berardi R; Catalano V; Graziano F; Barni S; Zaniboni A; Beretta GD; Labianca R; Cascinu S;
    Oncology; 2005; 68(2-3):212-6. PubMed ID: 16015036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.
    Yi JH; Kim H; Jung M; Shin SJ; Choi JS; Choi GH; Baik SH; Min BS; Kim NK; Ahn JB
    Oncology; 2013; 85(5):283-9. PubMed ID: 24217184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
    Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
    Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer.
    Jansman FG; Idzinga FS; Smit WM; de Graaf JC; Coenen JL; Sleijfer DT; Brouwers JR
    Clin Ther; 2005 Mar; 27(3):327-35. PubMed ID: 15878386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin].
    Zhou JF; Bai CM; Cheng YJ; Jia N; Shao YJ; Chen SC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Jun; 31(3):358-61. PubMed ID: 19621525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
    Petrioli R; Licchetta A; Roviello G; Pascucci A; Francini E; Bargagli G; Conca R; Miano ST; Marzocca G; Francini G;
    Cancer Invest; 2012 Jan; 30(1):65-71. PubMed ID: 22236191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience.
    Park SH; Sung JY; Han SH; Baek JH; Oh JH; Bang SM; Cho EK; Shin DB; Lee JH
    Jpn J Clin Oncol; 2005 Sep; 35(9):531-5. PubMed ID: 16027146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.